Anupam Rasayan Acquires Stake in Bliss GVS Pharma, Expands Pharma Platform
Anupam Rasayan reported highest ever revenue in FY'26 with operating cash flow of ₹334 crore. The company is acquiring 43.3%-48.2% stake in Bliss GVS Pharma to build a pharma platform. Q4 FY'26 consolidated revenue grew 26% YoY to ₹639 crore, and FY'26 revenue increased 65% YoY to ₹2,384 crore. The acquisition of Bliss GVS will be funded by ₹300 crore NCDs and quasi-equity.
The announcement involves a significant acquisition (Bliss GVS Pharma) and the release of earnings call transcript detailing strong financial performance and strategic diversification, which are material events for investors.
The company reported record revenues, strong operating cash flow, and significant growth driven by diversification and strategic acquisitions. The acquisition of Bliss GVS Pharma is viewed positively for expanding its pharmaceutical platform.
Anupam Rasayan India Limited (ARIL) announced the submission of the transcript of its Earnings Call on the Audited Financial Results for the quarter and financial year ended March 31, 2026. The call, held on May 25, 2026, discussed the company's performance and strategic initiatives.
During FY'26, Anupam Rasayan achieved its highest ever revenue, driven by strong execution, increased contribution from high-value chemistries, and the scale-up of commercial molecules. The company reported operating cash flow of ₹334 crore for FY'26. Anupam Rasayan has diversified its portfolio, with revenue from high-performance materials increasing threefold and Pharma revenue growing 15-fold between FY'22 and FY'26. The company's dependence on agrochemicals has reduced from 76% to 55% of revenue during the same period.
Key strategic developments include the completion of the acquisition of Jayhawk Fine Chemicals, which provides a U.S. manufacturing footprint and strengthens advanced custom synthesis capabilities. Furthermore, Anupam Rasayan has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma Limited, along with an open offer for up to 26% additional shares. This acquisition aims to build an integrated global life science and specialty pharmaceutical platform, strengthening Anupam Rasayan's presence across the pharmaceutical value chain.
Financially, for Q4 FY'26, consolidated income was ₹639 crore, a 26% year-on-year increase, with a Profit After Tax (PAT) of ₹56 crore. For the full FY'26, revenue from operations was ₹2,384 crore, a 65% year-on-year increase, with PAT of ₹222 crore. The company has completed its capex program with all plants commercialized and is not envisaging major future capex in the near term.
The acquisition of Bliss GVS Pharma will be funded through approximately ₹300 crore via non-convertible debentures and the balance through non-controlling, non-voting equity instruments. The company expects the acquisition to be EPS accretive from day 1. Anupam Rasayan anticipates a consolidated pro forma revenue of over ₹4,000 crore and an EBITDA of around ₹834 crore across its four key entities (Anupam, Tanfac, Jayhawk, and Bliss GVS Pharma). The company projects a standalone tax rate of approximately 25% going forward.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.